Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

Author's Avatar
Feb 21, 2023

Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with Nasdaq Listing Rules 5250(c)(2).